Literature DB >> 21317739

Finding ALK-positive lung cancer: what are we really looking for?

D Ross Camidge, Fred R Hirsch, Marileila Varella-Garcia, Wilbur A Franklin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21317739     DOI： 10.1097/JTO.0b013e31820cf068

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  9 in total

1.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Authors:  D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

Review 2.  Treating ALK-positive lung cancer--early successes and future challenges.

Authors:  D Ross Camidge; Robert C Doebele
Journal:  Nat Rev Clin Oncol       Date:  2012-04-03       Impact factor: 66.675

3.  Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target.

Authors:  Christina I Selinger; Bob T Li; Nick Pavlakis; Matthew Links; Anthony J Gill; Adrian Lee; Stephen Clarke; Thang N Tran; Trina Lum; Po Y Yip; Lisa Horvath; Bing Yu; Maija R J Kohonen-Corish; Sandra A O'Toole; Wendy A Cooper
Journal:  Histopathology       Date:  2016-11-15       Impact factor: 5.087

4.  The potential for crizotinib in non-small cell lung cancer: a perspective review.

Authors:  Yung-Jue Bang
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

5.  Targeting Anaplastic Lymphoma Kinase in GI Primary Malignancies.

Authors:  Jerold Loh; Yvonne Li En Ang; Amit Jain; Joe Yeong; Raghav Sundar
Journal:  JCO Precis Oncol       Date:  2022-07

Review 6.  Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer.

Authors:  Andrew J Weickhardt; Dara L Aisner; Wilbur A Franklin; Marileila Varella-Garcia; Robert C Doebele; D Ross Camidge
Journal:  Cancer       Date:  2012-12-20       Impact factor: 6.860

7.  Quantitative features of dual-energy spectral computed tomography for solid lung adenocarcinoma with EGFR and KRAS mutations, and ALK rearrangement: a preliminary study.

Authors:  Meng Li; Li Zhang; Wei Tang; Pei-Qing Ma; Li-Na Zhou; Yu-Jing Jin; Lin-Lin Qi; Ning Wu
Journal:  Transl Lung Cancer Res       Date:  2019-08

8.  The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

Authors:  A J Atherly; D R Camidge
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640

9.  Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.

Authors:  Jinghui Wang; Yiran Cai; Yujie Dong; Jingying Nong; Lijuan Zhou; Guimei Liu; Dan Su; Xi Li; Shafei Wu; Xuejing Chen; Na Qin; Xuan Zeng; Haiqing Zhang; Zongde Zhang; Shucai Zhang
Journal:  PLoS One       Date:  2014-07-03       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.